We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CP-690,550 Thorough QTc Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01743677
First Posted: December 6, 2012
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
  Purpose
ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development. The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation.

Condition Intervention Phase
Healthy Drug: CP-690,550 Drug: Placebo Drug: Moxifloxacin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 0.25 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 0.5 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 1 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 2 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 4 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 8 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 12 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 16 hr postdose ]
  • Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time [ Time Frame: 24 hr postdose ]

Secondary Outcome Measures:
  • Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo [ Time Frame: -1, -0.5, and 0 hrs predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hr postdose ]
  • Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo [ Time Frame: -1, -0.5, and 0 hrs predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hr postdose ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC(0-infinity)] [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUClast) [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Plasma Decay Half-Life (t1/2) [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC(0-infinity)] by CYP2C19 Genotype [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) by CYP2C19 Genotype [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Maximum Observed Plasma Concentration (Cmax) by CYP2C19 Genotype [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) by CYP2C19 Genotype [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]
  • Plasma Decay Half-Life (t1/2) by CYP2C19 Genotype [ Time Frame: predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose ]

Enrollment: 60
Study Start Date: November 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CP-690,550 100 mg Drug: CP-690,550
Single dose 100 mg (5 x 20 mg tablets)
Placebo Comparator: Placebo Drug: Placebo
Single dose placebo tablets (5 tablets)
Active Comparator: Moxifloxacin hydrochloride Drug: Moxifloxacin
Single dose Avelox 400 mg tablet

Detailed Description:
The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and/or female subjects between ages of 18 and 55 years, inclusive.
  • Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

  • Use of tobacco- or nicotine-containing products in excess of equivalent of 5 cigarettes per day.
  • 12-lead ECG demonstrating QTc >450 msec or other clinically significant abnormalities at Screening.
  • History of risk factors for QT prolongation or torsades de pointes.
  • Pregnant or nursing women; women of childbearing potential unwilling or unable to use an acceptable method of nonhormonal contraception from at least 14 days prior to first dose until completion of follow-up.
  • Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to first dose of trial medication.
  • Any clinically significant infections within past 3 months or evidence of infection in past 7 days.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01743677


Locations
Belgium
Pfizer Investigational Site
Bruxelles, Belgium, 1070
Singapore
Pfizer Investigational Site
Singapore, Singapore, 188770
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01743677     History of Changes
Other Study ID Numbers: A3921028
First Submitted: October 25, 2012
First Posted: December 6, 2012
Last Update Posted: October 12, 2017
Last Verified: December 2012

Keywords provided by Pfizer:
TQT study
CP-690,550

Additional relevant MeSH terms:
Moxifloxacin
Tofacitinib
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Protein Kinase Inhibitors